Accueil / Communiqués / Landos Biopharma to Present at Upcoming Investor Conferences

Landos Biopharma to Present at Upcoming Investor Conferences

Thursday, March 7th 2019 at 12:00pm UTC

BLACKSBURG, Va.–(BUSINESS WIRE)– Landos
Biopharma, Inc.
, a clinical-stage biopharmaceutical company focused
on the discovery and development of safer and more effective
first-in-class oral therapeutics for patients with autoimmune diseases,
announced that the Chairman and CEO, Dr. Josep Bassaganya-Riera, will
present a company update at the following conferences:

Cowen and Company 39th Annual Healthcare
Conference

Tuesday, March 12th at 11:00 a.m. ET
Webcast:
http://wsw.com/webcast/cowen52/lans/

Needham & Company 18th Annual Healthcare
Conference

Tuesday, April 9th at 11:40 a.m. ET
Webcast:
http://wsw.com/webcast/needham90/lans/

BioCentury Future Leaders in Biotech Conference
Friday,
April 12th

The Cowen and Needham presentations will be webcast live at the links
shown above and will be archived following the presentation on the Landos
website
.

“As we continue to build our financial position, we are excited to
present Landos’ therapeutic development pipeline for autoimmune diseases
and clinical development program in inflammatory bowel disease (IBD) at
these important investment conferences,” said Dr. Josep
Bassaganya-Riera, Chairman and CEO. “Our lead compound, BT-11 is a
first-in-class, oral, gut-restricted, investigational new drug for
Crohn’s Disease (CD) and Ulcerative Colitis (UC) that has the potential
to disrupt the current IBD treatment paradigm and address an unmet
clinical need for safer and more effective oral therapeutics for IBD. We
completed our Phase 1 clinical trial in 2018 and initiated our global
Phase 2 program for UC in the US and Europe.”

About Landos Biopharma
Landos Biopharma, Inc. is a
clinical-stage biopharmaceutical company focused on the discovery and
development of first-in-class oral therapeutics for patients with
autoimmune diseases. Landos’ lead clinical asset, BT-11, is a
first-in-class, oral therapeutic that acts locally in the
gastrointestinal tract for treatment of inflammatory bowel disease
(IBD). The company has completed Phase 1 clinical testing and initiated
a Phase 2 clinical program for BT-11 for treatment of UC and CD in 2019.
Landos also has a robust pipeline of new compounds for other autoimmune
diseases, several of which will advance to IND in 2019. Landos is
headquartered in Blacksburg, VA. For more information, please visit www.landosbiopharma.com
or contact info@landosbiopharma.com
or follow us @Landosbio.

Contacts

Landos Biopharma:
Josep Bassaganya-Riera
540.218.1767
jbr@landosbiopharma.com

For Media Requests:
Sharon Correia
LaVoieHealth Science
617.412.8779
scorreia@lavoiehealthscience.com

Source: Landos Biopharma, Inc.


Voir aussi

Innovations in Artificial Intelligence, Blockchain, Quantum Computing, Robots, and Catalysts, 2019 Study – ResearchAndMarkets.com

Friday, March 22nd 2019 at 3:01pm UTC DUBLIN–(BUSINESS WIRE)– The « Innovations in Artificial Intelligence, Blockchain, …